Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities—Which TKI is the safest?

Benzer Materyaller

• Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID‐19 pandemic
  Yazar:: Eşkazan, Ahmet Emre
  Baskı/Yayın Bilgisi: (2020)
• Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
  Yazar:: Mario Tiribelli, ve diğerleri
  Baskı/Yayın Bilgisi: (2019-08-01)
• Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
  Yazar:: Tiribelli, Mario, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• New drugs approved for acute myeloid leukaemia in 2018
  Yazar:: Kucukyurt, Selin, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta‐analysis
  Yazar:: Fachi, Mariana M., ve diğerleri
  Baskı/Yayın Bilgisi: (2019)